VEGF-зависимая антиангиогенная терапия в офтальмологии

1. Жуков Н.В. Современное состояние антиангиогенной терапии. Целевая терапия без мишени? ⁄⁄ Практическая онкология.— 2007.— Т. 8.— № 3.— С. 164-170.

2. Зиангирова Г.Г., Лихванцева В.Г. Особенности и роль ангиогенеза в опухолях ⁄⁄ Опухоли сосудистого тракта глаза.— М.: Последнее слово, 2003.— С. 456.

3. Andrew N.A., Lisa T., Carol Y.C. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.⁄⁄ Am. J. Ophthalmol.— 2008.— Vol. 145.— P. 862-874.

4. Anti-VEGF. Developments in Ophthalmology / Editors F. Bandello, M. Battaglia Parodi.— Karger, Switzerland, Basel, 2010.— Vol. 46.— P. 144.

5. Artunay O., Yuzbasioglu E., Raisier R. et al: Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection ⁄⁄ Eye.— L., 2009.— Vol. 23.— P. 2187-2193.

6. Avery R.L., Pieramici D.J., Rabena M.D. et al. The international intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety wordwide ⁄⁄ Br. J. Ophthalmol.— 2006.— Vol. 90.— P. 1344-1349.

7. Awata T., Inoue K., Kurihara S. et al. A common polymorphism in the 5-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes ⁄⁄ Diabetes.— 2002 —Vol. 51.— № 5— P. 1635-1639.

8. Boz M., Michels S., Geitzenauer W. et al: Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment ⁄⁄ Br. J. Ophthalmol.— 2007.— Vol. 91.— P. 785-789.

9. Carl D.R., David M.B., Prema A. et al. Randomized double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 ⁄⁄Am. J. Ophthalmol.— 2008.— Vol. 145.— P. 239-248.

10. Costa R.A., Jorge R., Calucci D. et al: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Stydy): results of a phase I dose-escalation study ⁄⁄ Invest Ophthalmol Vis Sci.— 2006.— Vol. 46.— P. 4569-4578.

11. D Amore P.A. Vascular Endothelial Cell Growth Factor-A Not Just for Endothelial Cells Any more ⁄⁄ Am. J. Pathol.— 2007.— Vol. 159.— P. 2345-2354. http:⁄⁄www.sciencedaily.com/releases/2008/11/081103111538.htm.

12. D Amore P. Anti-VEGF Drugs For Retinal Diseases Could Have Serious Side Effects. Scientists Caution ⁄⁄ Science Daily.— 2008.— Nov. 5.

13. Do D.V. Antiangiogenic approaches to age-related macular degeneration in future ⁄⁄ Ophthalmology.— 2009.— Vol. 116.— Suppl. 1.— S. 24-26.

14. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands ⁄⁄ Nature.— 1990.— Vol. 346.— P. 818-822.

15. Eyetech Study Group: Preclinical and phase IA clinical evalution of anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration ⁄⁄ Retina.— 2002.— Vol. 22.— P. 143-152.

16. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal neovascularization secondary to age-related macular degeneration: phase II study results ⁄⁄ Ophthalmology.— 2003.— Vol. 110.— P. 979-986.

17. Fong G.H., Rossant J., Gertenstein M. et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium ⁄⁄ Nature.— 1995.— Vol. 376.— P. 66-70.

18. Heiduschka P., Fietz H., Hofmeister S. et al: Penetration of bevacizumab through the retina after intravitreal injection in the monkey ⁄⁄ Invest Ophthalmol. Vis Sci.— 2007.— Vol. 483.— P. 2814-2823.

19. Jin K., Zhu Y., Sun Y. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo ⁄⁄ Proc. Nat. Acad. Sci.— 2002.— Vol. 99.— P. 11946-11950.

20. Jin K.L., Mao X.O., Greenberg D.A.Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia ⁄⁄ Proc. Nat. Acad. Sci. USA.— 2000.— Vol. 97.— № 18.— P. 10242-10247.

21. Kabbinavar F., Hurvitz H.I., Novotny W. et al. Bevasizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer ⁄⁄ N. Engl. J. Med.— 2004.— Vol. 350.— P. 2335-2342.

22. Lalwani G.A., Rosenfeld P.J., Fung A.E. et al. A variable —dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study ⁄⁄ Am. J. Ophthalmol.— 2009.— Vol. 48.— P. 43-58.

23. Magali Saint-Geniez, Arindel S. R. Maharaj, Tony E. Walshe et al. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Muller Cells and Photoreceptorshttp: www.plosone.org/article/info:doi/10.1371/journal.pone.0003554.

24. Michels S., Rosenfeld P.J., Puliafito C.A. et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration 12-week results of an uncontrolled open-label clinical study ⁄⁄ Ophthalmology.— 2005.— Vol. 112.— P. 1035-1047.

25. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A. et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration 24-week results of an uncontrolled open-label clinical study ⁄⁄ Ophthalmology.— 2006.— Vol. 113.— P. 2002-2012.

26. Paccola L., Costa R.A., Folgosa M.S. et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema IBEME study) ⁄⁄ Br. J. Ophthalmology.— 2008.— Vol. 92.— P. 76-80.

27. Presta L.G., Chen H., O’Connor S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumor and other disorders ⁄⁄ Cancer Res.— 1997.— Vol. 57.— P. 4593-4599.

28. Rich R.M., Rosenfeld P.J., Puliafito C.A. et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration ⁄⁄ Retina.— 2006.— Vol. 26.— P. 495-511.

29. Reich S.J., Fosnot J., Kuroki A. et al. Small interfering RNA targeting VEGF effectively inhibits ocular neovascularization in a mouse model ⁄⁄ Mol. Vas.— 2003.— Vol. 9.— P. 210-216.

30. Rosenfeld P.J., Fung A.E., Puliafito C.A. et al. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion ⁄⁄ Ophthalmic Surg. Lasers Imaging.— 2005.— Vol. 36.— P. 336-339.

31. Rosenfeld P.J. Ranibizumab for neovascular age-related macular degeneration ⁄⁄ N. Engl. Med.— 2006.— Vol. 355.— P. 1419-1431.

32. Sbalaby F., Rossant J., Yamagushi T.P. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice ⁄⁄ Nature.— 1995.— Vol. 376.— P. 62-66.

33. Schmidt-Erfurth U., Eldem B., Guymer R. et al. On behalf of the EXCITE Stydy Group: Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration ⁄⁄ Am. J. Ophthalmology.— 2010.— Vol. 149.— № 2.— P. 307-315.

34. Shahar J., Rosenfeld P.J., Pulafito C.A. et al: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin) ⁄⁄ Retina.— 2006.— Vol. 26.— P. 262-269.

35. Shen J., Samul R., Silva R.L. et al. Supression of ocular neovascularization with sirRNA targeting VEGF receptor 1 ⁄⁄ Gen. Ther.— 2006.— Vol. 13.— P. 222-234.

36. Singerman L.J. Intravitreal bevasiranib in exudative age-related macular degeneration or diabetic macular edema ⁄⁄ 25 Annual Meeting at the American Society of Retinal Specialists, Indian Wells.— 2007.— Plen. rep. subm.— P. 14.

37. Singerman L.J. Combination therapy using the small interfering RNA bevasiranib ⁄⁄ Retina.— 2009.— Suppl. 49.— Р. 50.

38. Spaide R.F., Laud K., Fine H.F. et al: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration ⁄⁄ Retina.— 2006.— Vol. 26.— P. 389-390.

39. Szaflik J.P., Wysocki T., Kowalski M. et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy ⁄⁄ Graefes Arch. Clin. Exp. Ophthalmol.— 2008.— Vol. 246.— № 1.— P. 39-43.

40. Yenerel N.N., Dine U.A., Corgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection ⁄⁄ J. Ocul. Pharmac. Ther.— 2008.— Vol. 24.— P. 362-363.

41. Yamashiro K., Tsajikawa A., Miamoto K. et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch ⁄⁄ Retina.— 2010.— Vol. 30.—P. 485-490.

42. Weigert G., Michels S., Sacu S. et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamsinolone for neovascular age-related macular degeneration: 6-month resulta of a prospective, randomized, controlled clinical study ⁄⁄ Br. J. Ophthalmology.— 2008.— Vol. 92.— P. 356-360.

Поступила 04.10.2010